Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Biologics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CAPRIN1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CAPRIN1 Recombinant Protein High purity (>95%), Endotoxin Controlled, Sequence Verified. HEK293 expressed for native post-translational modifications. |
View CAPRIN1 Products |
| Gene Delivery | CAPRIN1 Lentivirus Premade Particles Full-length ORF for stable cell line construction to validate cell-surface expression and binding. |
View CAPRIN1 Products |
| Benchmark Ab | Anti-CAPRIN1 Recombinant Antibody Sequence derived from clinical benchmark (TRK-950). Ideal positive control for binding and ADCC assays. |
View CAPRIN1 Products |
| Validator | CAPRIN1 siRNA Set Target-specific knockdown pool for specificity and functional validation. |
View CAPRIN1 Products |
| Related Target A | G3BP1 Essential partner interacting with CAPRIN1 in stress granules; critical for understanding translation regulation under cellular stress. |
View G3BP1 Products |
| Related Target B | YBX1 Multifunctional RNA-binding protein co-expressed and translocated to the cell surface in multiple aggressive cancers. |
View YBX1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Atypical Cell-Surface Conformation | Lentivirus-driven stable cell line generation preserves native membrane-associated folding. |
| Cross-Species Cross-Reactivity | Human, Mouse, and Cynomolgus ortholog proteins available with high purity (>95%). |
| Lack of Validated Positive Controls | Clinical-grade benchmark antibody (TRK-950 sequence) ready for assay calibration. |
| Off-Target Binding & False Positives | Sequence-verified proteins and target-specific siRNA pool for background signal subtraction. |
Live CAPRIN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CAPRIN1 (Cell Cycle Associated Protein 1) represents a paradigm shift in oncology. While historically classified as an intracellular RNA-binding protein involved in translation regulation and stress granule formation, CAPRIN1 is selectively translocated to the cell membrane in various solid tumors—including breast, gastric, and colorectal cancers—while remaining strictly intracellular in normal tissues. This cancer-specific cell-surface expression makes it an exceptionally safe and highly selective target for antibody-based therapeutics.
The race for CAPRIN1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and combination regimens. As first-generation therapies reach the clinic, the next wave of R&D is targeting optimized internalization kinetics and enhanced antibody-dependent cellular cytotoxicity (ADCC) to exploit the unique membrane presentation of this target.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Toray Industries (TRK-950) | Gastric, Breast, Lung Cancers | ADCC & CDC Assays (Requires stable cell lines via Lentivirus and positive control benchmark antibodies) |
| Antibody-Drug Conjugate (ADC) | Biotech Consortia | Refractory Solid Tumors | Internalization Assay (Requires sequence-verified recombinant proteins and stable cell lines for kinetic profiling) |
| Combination Therapies | Clinical Investigators | Advanced Metastatic Cancers | Synergy Validation (Requires target knockdown via validated siRNA to isolate CAPRIN1-specific therapeutic effects) |